PET scan for PSMA/FAP-positive cancer
This trial tests a special PET scan using a tracer that attaches to certain markers (PSMA and FAP) found on some cancers. It aims to help doctors see where the cancer is, possibly leading to better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a known or suspected cancer that shows signs of certain markers (PSMA or FAP) on prior scans or tests.
- You cannot be pregnant.
- You must not have a known allergy to the study tracer medicine (68Ga-PSFA).
- You or your legal guardian must agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
This study is testing a new type of PET scan that uses a special tracer to make tumors easier to see. It may help doctors get more accurate information about your tumor before you have a biopsy or surgery.
This study compares two special PET/CT scan tracers—68Ga-FAPI-LM3 and 18F-FDG—to see how well they detect cancer that shows FAP or SSTR2 signals. It may help doctors choose better imaging to find or assess certain tumors.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.